| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 interim results example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Genmab A/S$29
-0.8 (-2.69%)
B 62Pipeline Score Overvalued Biotech · Commercial
Market Cap
15.94 B
EPS
1.34
P/E Ratio
20.26 $
Value Trade
32.73 M
0.11 %
Week
-4.21 %
1 Month
-7.47 %
3 Month
-11.14 %
6 Month
-31.45 %
5 Year
612.35 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
4.93 M
52 Week Range
20.23 - 35.43
% held by Insiders
0.52 %
% held by Institutions
13.46 %
Enterprise Value
19.77 B
Total Shares
594.91 M
Short %
1.45 %
Float Shares
591.84 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genmab A/S
407Total events
5Upcoming
168Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 5
TBD
T3Poster Presentation
NHL-6: Phase 2 study of subcutaneous epcoritamab as outpatient treatment for 2L+ R/R DLBCL
Event history 402
Jul 6, 2026
▲EU ApprovalTEPKINLYApprovedEx-US Regulatory
EC approval of TEPKINLY in combination with lenalidomide and rituximab for R/R FL
relapsed or refractory follicular lymphomasource ↗
Jun 29, 2026
▲Topline ReadoutEpcoritamabApprovedClinical Data
Topline results from Phase 3 EPCORE DLBCL-4 trial of epcoritamab plus lenalidomide demonstrate statistically significant improvement in progression-free survival
relapsed/refractory diffuse large B-cell lymphomasource ↗
Jun 29, 2026
▲Primary Endpoint MetEpcoritamabApprovedClinical Data
Topline results: statistically significant improvement in progression-free survival
relapsed/refractory diffuse large B-cell lymphomasource ↗
Jun 14, 2026
◆Oral PresentationEpcoritamabApprovedPresentation
Fixed duration venetoclax plus epcoritamab: interim analysis of randomized HOVON 165/AETHER trial in R/R CLL/SLL
relapsed/refractory CLL/SLLsource ↗
Jun 13, 2026
▲Oral PresentationEpcoritamabApprovedPresentation
Epcoritamab monotherapy and combination regimens data presented at EHA 2026
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
Jun 13, 2026
◆Poster PresentationEpcoritamabApprovedPresentation
Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed LBCL and comorbidities: results from EPCORE DLBCL-3
relapsed/refractory diffuse large B-cell lymphomasource ↗
Jun 12, 2026
◆Oral PresentationEpcoritamabApprovedPresentation
Full results from Phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy to investigator's choice chemotherapy in R/R LBCL
relapsed/refractory large B-cell lymphomasource ↗
Jun 12, 2026
◆Poster PresentationEpcoritamabApprovedPresentation
Reduced CD20 expression and intratumoral CD3+ T cells following epcoritamab treatment are associated with progressive disease in a subset of DLBCL and FL
relapsed/refractory diffuse large B-cell lymphoma and follicular lymphomasource ↗
Jun 11, 2026
◆Oral PresentationEpcoritamabApprovedPresentation
Presentation of EPCORE FL-1 subgroup data for epcoritamab + R2
Relapsed or Refractory Follicular Lymphomasource ↗
Jun 1, 2026
◆Poster PresentationEpcoritamabApprovedPresentation
Epcoritamab + chemoimmunotherapy in patients with R/R LBCL eligible for ASCT: pooled results from Arms 4 and 10 of EPCORE NHL-2
relapsed/refractory large B-cell lymphomasource ↗
Jun 1, 2026
◆Poster PresentationRina-SPresentation
RAINFOL-04: Phase 3 study of rinatabart sesutecan plus SOC vs SOC as maintenance treatment after second-line platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
recurrent platinum-sensitive ovarian cancersource ↗
May 31, 2026
◆Poster PresentationpetosemtamabPresentation
Petosemtamab plus pembrolizumab as first-line treatment of PD-L1 high metastatic NSCLC: global phase 2 trial
PD-L1 high metastatic non-small cell lung cancersource ↗
Drug Pipeline Intelligence
B62
Pipeline Score $11.0B
Pipeline ValueOvervalued
Valuation Signal17
Drugs Scored0.7x
rNPV / MCap Top 90%
Mid Cap (rank 92 of 911)
Percentile RankGenmab A/S holds a solid B-grade pipeline (62/100), with $13.1B risk-adjusted pipeline value, led by Acasunlimab in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acasunlimab Small molecule | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | NCT06635824 | 42% | $4.7B | ACTIVE NOT_RECRUITING | 191 | AVERAGE | D (24) | Sep 1, 2028 | ELEVATED_RISK | Mar 11, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
epcoritamab | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p value < 0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p value < 0.0001 Read More | Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Read More | |
epcoritamab | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p value < 0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p value < 0.0001 Read More | Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Read More | |
epcoritamab | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | 2026-06-29 | 60%; HR 0.40 [95% CI 0.30, 0.55]; p value < 0.0001; 56%; HR 0.44 [95% CI 0.33, 0.60]; p value < 0.0001 Read More | Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GMAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GMAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GMABGenmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab has announced that its drug TEPKINLY® (epcoritamab), when used in combination with lenalidomide and rituximab, has been approved by the European Commission. This approval is specifically for the treatment of relapsed or refractory follicular lymphoma. The combination therapy is expected to enhance treatment options for patients suffering from this condition.
Read more →GMAB▲ +5.6%on this newsshared move
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, showing that the combination of epcoritamab and lenalidomide significantly improves progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The trial met its primary objective, reducing the risk of disease progression and death by 60%. The company plans to engage regulatory authorities for further advancement.
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement
Genmab A/S will increase its share capital by 185 shares due to the exercise of employee warrants, with no preemption rights for existing shareholders. The shares were subscribed at a price of DKK 1,334.50 each, resulting in proceeds of around DKK 0.2 million. This capital increase represents less than 0.001% of the company's share capital and will be completed shortly. The new shares will be ordinary and freely transferable, and they will grant rights to dividends effective immediately upon subscription.
Read more →GMABMajor Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A S
Genmab A S has announced that Orbis Investment Management Limited controls 4.99% of its share capital and voting rights, as of June 12, 2026. This announcement is in compliance with the Danish Capital Markets Act's reporting requirements. Genmab, known for its commitment to improving cancer treatment through antibody medicines, is also advancing a robust clinical pipeline, including various antibody-based therapeutic formats. The company continues to build on over 25 years of experience in this field.
Read more →GMABGenmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab has announced findings regarding Epcoritamab's effectiveness in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The article highlights monotherapy and combination regimens showing high response rates. However, specific details about the study's results and implications are not provided.
Read more →GMABGenmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab has presented data on the EPCORE FL-1 subgroup, showing consistent efficacy and safety results for Epcoritamab when combined with Rituximab and Lenalidomide in patients with relapsed or refractory follicular lymphoma. The findings suggest a potential treatment option for this patient population, although specific details on outcomes were not provided.
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement
Genmab A S announced the granting of restricted stock units and warrants to its employees as part of their compensation strategy. A total of 15,894 restricted stock units and 15,494 warrants have been awarded, with each stock unit having a fair value of DKK 1,616.50 and warrants priced the same. The stock units will vest after three years, while the warrants expire after seven years. This decision reflects Genmab's commitment to retaining talent and fostering long-term employee engagement.
Read more →GMABTransactions with Shares and Linked Securities in Genmab A S Made by Managerial Employees and Their Closely Associated Persons Company Announcement
Genmab A/S has announced transactions involving its shares conducted by managerial employees and their closely associated persons. The transactions, made under a power of attorney given to the company, include the sale of shares valued at a total of DKK 1,734.75. The disclosure aligns with regulatory requirements and emphasizes transparency within the company. Additionally, Genmab continues to develop a robust pipeline of antibody medicines aimed at treating serious diseases such as cancer.
Read more →GMABGenmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab is set to showcase its advancements in oncology at two major upcoming events: the 2026 ASCO Annual Meeting and the EHA 2026 Congress. The company aims to highlight its innovative approaches and research findings in the field. Details on specific presentations or data have not been disclosed.
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2026
Genmab reported a 25% increase in revenue for Q1 2026, reaching $896 million, driven by higher royalties from DARZALEX and Kesimpta. The FDA approved an sBLA that removes the hospitalization requirement for certain DLBCL patients. Despite a slight decrease in operating profit, the company remains focused on advancing its late-stage portfolio and preparing for upcoming product launches.
Read more →GMABGenmab A S Share Capital Reduction Company Announcement
Genmab A S announced a reduction in its share capital by DKK 1,900,000 through the cancellation of 1,900,000 shares. This decision was made during the company's Annual General Meeting on March 19, 2026, and has been registered with the Danish Business Authority. Following the capital reduction, Genmab's total nominal share capital will be DKK 62,350,721, consisting of 62,350,721 shares. The company is known for its commitment to developing innovative therapies for cancer and other serious diseases.
Read more →GMABGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab A/S presented new data on rinatabart sesutecan (Rina-S) in combination with bevacizumab for advanced ovarian cancer at the SGO Annual Meeting. The Phase 1/2 RAINFOL-01 study demonstrated a safety profile consistent with known profiles of both drugs, suggesting potential for improved disease management. The combination was tolerable, with manageable adverse events reported.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026 Company Announcement Net sales of DARZALEX in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net
Genmab A/S announced a significant increase in net sales of its flagship product DARZALEX, totaling USD 3,964 million for the first quarter of 2026. This figure includes USD 2,208 million in net sales from the U.S. market and USD 1,756 million from international sales. The company receives royalties on these worldwide net sales from Johnson & Johnson under an exclusive license agreement for the development and commercialization of daratumumab. Genmab continues to advance its mission in antibody-based therapies with a strong clinical pipeline aimed at improving cancer treatment.
Read more →GMABGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab announced positive results from the Phase 1/2 RAINFOL-01 trial, indicating that rinatabart sesutecan (Rina-S) combined with bevacizumab is tolerable for patients with advanced ovarian cancer. The study showed no new safety signals and a manageable safety profile. The ongoing Phase 3 RAINFOL-04 trial will further assess this combination in recurrent platinum-sensitive ovarian cancer.
Read more →GMABMajor Shareholder Announcement
Genmab A/S has announced that Orbis Investment Management Limited now controls 5.01% of its voting rights, equivalent to 3,221,620 shares. This major shareholder announcement highlights the increasing interest from institutional investors in Genmab. The company, known for its innovative antibody medicines, is focused on delivering transformative treatments for cancer and serious diseases.
Read more →GMABPassing of Genmab A S' Annual General Meeting Company Announcement At Genmab A S' Annual General Meeting held today
Genmab A/S held its Annual General Meeting on March 19, 2026, where significant resolutions were made including the approval of the 2025 Annual Report and the re-election of six Board members. The company's profits amounting to USD 963 million will be carried forward to retained earnings. Additionally, a proposal to reduce the share capital by cancelling treasury shares was adopted. However, a proposal regarding Board remuneration for 2026 was withdrawn, indicating potential governance issues that may need addressing.
Read more →GMABConstitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab A/S held its Annual General Meeting on March 19, 2026, where it appointed Ms. Deirdre P. Connelly as Chair and Ms. Pernille Erenbjerg as Deputy Chair of the Board of Directors. The company also announced the grant of 5,213 restricted stock units and 4,485 warrants to employees, aimed at enhancing employee motivation and retention. These grants are subject to specific vesting conditions and are part of Genmab's ongoing commitment to its workforce.
Read more →GMABCompletion of Share Buy-back Program Company Announcement
Genmab A/S has completed its share buy-back program, which was initiated on February 17, 2026, allowing for the repurchase of up to 342,130 shares. The program, with a total value of 725 million DKK, concluded on March 13, 2026, having successfully acquired a total of 342,130 shares at an aggregate value of 615,105,001 DKK. Following the buy-back, Genmab holds 2,859,663 shares as treasury shares, equating to 4.45% of its total share capital. This move underscores the company’s potential for robust financial health and continued dedication to enhancing shareholder value.
Read more →GMABTransactions in Connection with Share Buy-back Program
Genmab A/S has initiated a share buy-back program to repurchase up to 342,130 shares, valued at DKK 725 million, to fulfill commitments under its Restricted Stock Unit program. The program is set to conclude by March 31, 2026. Recent transactions have corrected the accumulated share buy-back figure to 148,000 shares, with Genmab holding 2,766,533 shares as treasury shares.
Read more →GMAB▼ -6.7%on this news
Correction to Company Announcement No. 13 of March 2, 2026
Genmab A/S issued a correction to its previous announcement regarding share transactions by managerial employees, clarifying that the correct share price was DKK 1,867.50 instead of DKK 0.00. This announcement aligns with regulatory requirements and highlights the company's commitment to transparency in its financial dealings. The company continues to focus on developing innovative antibody medicines.
Read more →GMABGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 27, 2026
Genmab A/S announced the grant of 587,495 restricted stock units and 455,004 warrants to its management and employees. The stock units will vest after three years based on performance criteria, while the warrants will also vest after three years and expire after seven. This initiative aims to align employee interests with company performance.
Read more →GMABCorrection to Company Announcement No. 13 of
Genmab A/S issued a correction to Company Announcement No. 13, clarifying the share price involved in trades by managerial employees. Originally reported as DKK 0.00, the correct price is DKK 1,867.50. The announcement details the vesting and settlement of restricted stock units for three executives, reaffirming their investment in the company. This correction aims to enhance transparency in the company's transaction reporting.
Read more →GMABGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement
Genmab A/S has announced the granting of 587,495 restricted stock units and 455,004 warrants to management and employees. The restricted stock units will vest after three years and are tied to performance criteria, aligning employee objectives with company growth. Each warrant, which also vests in three years, allows employees to subscribe to shares at the exercise price. This move reflects Genmab's dedication to employee engagement and its commitment to advancing innovative therapies for serious diseases.
Read more →GMABGenmab to Participate in Upcoming March 2026 Investor Conferences
Genmab A/S announced that its Executive Committee will participate in fireside chats at investor conferences in March 2026. The presentations will be available via live and archived webcasts on Genmab's website. The company continues to focus on developing innovative antibody therapeutics to improve patient outcomes.
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise - February 24, 2026
Genmab A/S announced a capital increase of 12,313 shares due to employee warrant exercises. This increase will not affect existing shareholders' preemption rights and is expected to generate around DKK 17.1 million for the company. The new shares will be listed on Nasdaq Copenhagen and provide rights to dividends and other company benefits.
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S has disclosed transactions involving shares by managerial employees and their closely associated persons, as required by market regulations. The company has been granted power of attorney to publish these trading activities. Genmab continues to focus on developing innovative antibody-based therapies for cancer and other serious diseases.
Read more →GMABGenmab Announces Initiation of Share Buy-Back Program
Genmab A/S has announced the initiation of a share buy-back program to fulfill commitments under its Restricted Stock Unit program. The program will commence on February 18, 2026, and is expected to conclude by March 31, 2026. Genmab plans to repurchase up to 342,130 shares for a total value of 725 million DKK, executed independently by Danske Bank.
Read more →GMABNotice to Convene the Annual General Meeting of Genmab A S Company Announcement Genmab A S to hold Annual General Meeting on Thursday
Genmab A S is set to hold its Annual General Meeting on March 19, 2026, at the Copenhagen Marriott Hotel. The agenda will cover various resolutions including the adoption of the audited Annual Report for 2025 and the distribution of profits. Shareholders will also vote on the re-election of Board members and approval of remuneration. The meeting highlights Genmab's commitment to transparency and shareholder engagement.
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab - January 29, 2026
Genmab A/S announced the grant of 32,806 restricted stock units and 34,307 warrants to its employees. The restricted stock units will vest after three years, while the warrants will also vest after the same period and expire seven years post-grant. This initiative reflects Genmab's commitment to incentivizing its workforce amidst ongoing clinical development challenges.
Read more →GMAB▲ +5.2%on this news
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Genmab A/S announced that worldwide net sales of DARZALEX (daratumumab) reached USD 14,351 million in 2025, with significant contributions from both U.S. and international markets. The company receives royalties from these sales under its exclusive license agreement with Johnson & Johnson. Genmab is focused on developing innovative antibody medicines and has a strong pipeline of late-stage clinical programs.
Read more →GMABGenmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab, a bispecific antibody for relapsed/refractory DLBCL. The study showed improved progression-free survival and other efficacy measures compared to standard treatments. However, overall survival did not achieve statistical significance. Further analysis and future presentations are planned.
Read more →GMABGenmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement Based on the topline r
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-1 trial, showcasing improvement in progression-free survival for its drug, epcoritamab, in patients with relapsed refractory diffuse large B-cell lymphoma. This trial is notable as it is the first of its kind to demonstrate such results for a bispecific antibody monotherapy in this patient population. The study involved 483 patients and compared epcoritamab to the investigator's choice of chemotherapy. Genmab plans to engage with global regulatory authorities regarding the next steps following these results.
Read more →GMABGenmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Genmab A/S has partnered with Anthropic to enhance its research and development through advanced AI solutions. The collaboration aims to streamline clinical development processes by utilizing Claude-powered AI for data processing and document generation. This initiative is expected to reduce manual burdens and allow Genmab's teams to focus on critical scientific tasks, ultimately accelerating the delivery of therapies to patients.
Read more →GMABGenmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Genmab A/S announced that CEO Jan van de Winkel will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will provide a company update and will be available via a live and archived webcast on Genmab's website. The company is known for its innovative antibody medicines and has a robust late-stage clinical pipeline.
Read more →GMABGenmab Portfolio Prioritization Update
Genmab A/S has announced the discontinuation of its acasunlimab program to concentrate on its late-stage pipeline, which includes EPKINLY, petosemtamab, and Rina-S. This strategic decision aims to allocate resources to the most promising opportunities in their portfolio. The company remains optimistic about the potential impact of its prioritized programs while maintaining its financial guidance for 2025.
Read more →GMABGenmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher impact opportunities across Ge
Genmab A/S has announced the discontinuation of the clinical development of acasunlimab following a portfolio review aimed at concentrating on higher impact opportunities. Despite the encouraging data observed for acasunlimab, the company opted to focus resources on other late-stage programs such as EPKINLY and petosemtamab. This strategic decision reflects Genmab's commitment to maximizing value for patients and shareholders. Importantly, the decision does not impact the company's financial guidance for the year 2025.
Read more →GMABGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Genmab A/S has successfully completed its tender offer for Merus N.V., acquiring 94.2% of its outstanding shares. This strategic acquisition aims to enhance Genmab's growth and revenue diversification, particularly through the development of petosemtamab, which is expected to launch in 2027. A subsequent offering period has been initiated for additional shares.
Read more →GMABGenmab to Hold 2025 R&D Update and ASH Data Review Meeting
Genmab A/S is set to hold its 2025 R&D Update and ASH Data Review Meeting on December 11, 2025. The virtual event will be available via live webcast, allowing global participation. Genmab aims to enhance patient outcomes through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030.
Read more →GMABGenmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Genmab announced promising results from clinical trials of epcoritamab, showing high response rates in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The EPCORE NHL-2 trial demonstrated an overall response rate of 93% and 98% in newly diagnosed DLBCL patients. Additionally, the three-year overall survival rate for FL patients was reported at 96%. The results highlight the potential of epcoritamab as a key treatment option in these malignancies.
Read more →GMABGenmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Genmab announced positive results from the Phase 3 EPCORE FL-1 trial, showing that EPKINLY (epcoritamab) combined with rituximab and lenalidomide significantly improves outcomes for patients with relapsed or refractory follicular lymphoma. The combination therapy reduced the risk of disease progression by 79% and achieved a 95% overall response rate. These findings were presented at the ASH Annual Meeting and published in The Lancet.
Read more →GMABTransactions With Shares and Linked Securities in Genmab A S Made by Managerial Employees and Their Closely Associated Persons Company Announcement
Genmab A S has disclosed recent transactions in its shares by managerial employees and their closely associated persons, in compliance with market regulations. The transactions involved acquisitions due to the vesting of restricted stock units at a share price of DKK2,043. Key individuals such as members of the Board of Directors participated in these transactions, with details reported on their respective acquisitions. The announcement came on December 1, 2025, highlighting continued engagement from management with company equity.
Read more →GMABTransactions with shares and linked securities in Genmab A S made by managerial employees and their closely associated persons Company Announcement
Genmab A S disclosed transactions involving its shares by managerial employees and closely associated persons, upholding regulatory compliance. On November 19, 2025, managerial employees exercised their power of attorney permitting the company to publish details of their trading activities. Included were sales of shares at prices of DKK 1,960 to DKK 1,960.50. No specific risks related to these transactions were mentioned in the announcement.
Read more →GMABGenmab Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma Company Announc
Genmab announced the FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma. This marks a significant milestone as it is the first bispecific therapy approved by the FDA for this indication. The approval is based on the Phase 3 EPCORE FL-1 study, which demonstrated superior efficacy of EPKINLY + R2 compared to standard care, with higher rates of progression-free survival and overall response. Despite its effectiveness, the treatment is associated with safety warnings regarding potential serious side effects.
Read more →GMABGenmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
Genmab A/S has announced a proposed offering of $1.5 billion in senior secured notes and $1.0 billion in senior unsecured notes, alongside a $2.0 billion senior secured term loan facility. The funds will be used to finance the acquisition of Merus N.V. and related expenses. The offering is subject to market conditions and will not be registered under the Securities Act.
Read more →GMABGenmab Announces Financial Results for the Nine Months of 2025
Genmab reported a strong financial performance for the first nine months of 2025, with revenue reaching $2,662 million, a 21% increase from the previous year. Significant developments included the successful Phase 3 trial of Epcoritamab and the FDA granting Breakthrough Therapy Designation to Rina-S. The company also announced a proposed acquisition of Merus N.V., aiming to enhance its late-stage pipeline with the addition of petosemtamab. Despite rising costs associated with expanding their product pipeline, Genmab maintains its financial guidance for 2025.
Read more →GMABGenmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
Genmab A/S announced that its CEO Jan Van de Winkel and CFO Anthony Pagano will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025. The event will be available via webcast on Genmab's website. The company aims to improve patient lives with innovative antibody therapeutics.
Read more →GMABGenmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Genmab A/S announced that over 20 abstracts on epcoritamab will be presented at the 2025 ASH Annual Meeting. The data will showcase its clinical profile and potential use in earlier therapy lines for B-cell non-Hodgkin’s lymphoma. Notably, pivotal results from the Phase 3 EPCORE FL-1 trial will also be shared, emphasizing the drug's efficacy in combination therapies.
Read more →GMABGenmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Genmab A/S has initiated a cash tender offer to acquire all outstanding shares of Merus N.V. for $97.00 per share. This offer follows a transaction agreement signed on September 29, 2025. The offer will expire on December 11, 2025, unless extended. Merus's Board recommends shareholders accept the offer.
Read more →GMAB▼ -7.9%on this newsshared move
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Genmab A/S announced promising results from the Phase 1/2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S) in patients with advanced endometrial cancer. The study reported a 50% confirmed objective response rate, including complete responses, in heavily pretreated patients. The results, presented at the ESMO Congress, suggest Rina-S may provide new treatment options for this patient population.
Read more →GMABGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
Genmab A/S reported net sales of DARZALEX (daratumumab) totaling USD 3,672 million for the third quarter of 2025. The sales included USD 2,088 million from the U.S. and USD 1,584 million from other regions. Genmab earns royalties on these sales under an exclusive license with Johnson & Johnson for the development and commercialization of daratumumab.
Read more →GMABGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Genmab A/S has announced its intention to acquire Merus N.V. for approximately USD 8.0 billion, enhancing its late-stage pipeline with the addition of petosemtamab, a promising therapy for head and neck cancer. The acquisition, approved by both companies' boards, aims to accelerate Genmab's transition to a wholly owned model and is expected to close by early 2026. The deal is anticipated to drive significant growth and revenue potential for Genmab into the next decade.
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab A/S has announced the grant of 14,353 restricted stock units and 9,681 warrants to its employees. The restricted stock units will vest after three years, while the warrants will also vest after the same period and expire seven years post-grant. This initiative aims to enhance employee retention and align their interests with the company's growth.
Read more →GMAB▲ +5.5%on this news
Genmab Announces Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed Refractory (R R) Follicular Lymphoma (FL) Company Announcement
Genmab's Phase 3 EPCORE FL-1 clinical trial demonstrated positive outcomes for its drug epcoritamab in combination with rituximab and lenalidomide in patients with relapsed refractory follicular lymphoma. The trial met its dual primary endpoints, showing statistically significant improvements in overall response rate and progression-free survival. In light of these results, the U.S. FDA has accepted a supplemental Biologics License Application for priority review, with a target action date set for November 30, 2025. If approved, this combination therapy will represent a new treatment option for patients in need.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 Company Announcement Net sales of DARZALEX in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide ne
Genmab A/S reported net sales of DARZALEX, totaling USD 3,539 million for the second quarter of 2025. The sales figure includes USD 2,017 million from the U.S. and USD 1,521 million from international markets. Genmab receives royalties on worldwide sales from Johnson & Johnson, under a collaborative agreement for the development and commercialization of daratumumab-related products. The company is dedicated to advancing its innovative antibody therapies, aiming to significantly impact cancer treatment by 2030.
Read more →GMABTransactions in Connection with Share Buy-back Program Company Announcement
Genmab A S has commenced a share buy-back program aimed at repurchasing up to 2.2 million shares, with expectations to conclude the initiative by July 10, 2025. From June 16 to June 20, 2025, the company executed transactions totaling 500 shares at various prices, accumulating over 2 million shares repurchased under the program. Currently, Genmab holds 2,532,938 shares as treasury shares, representing 3.95% of its total share capital and voting rights. This move is in line with their strategy to enhance shareholder value and manage capital efficiently.
Read more →GMAB(a) APPENDIX Share buy-back programme - Specification for May 19 - 23, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A S 19-May-2025 10 26 31 AM 34 1313.00 XCSE GENMAB A S 19-May-2025 10 26 31 AM 49 1313.00
Genmab A/S has announced a detailed specification for its share buy-back program scheduled for May 19 to 23, 2025. The program includes various transactions executed at different times and prices on the XCSE. This initiative reflects Genmab's strategy to enhance shareholder value by repurchasing its shares. The buy-back plan signifies the company's confidence in its financial performance.
Read more →GMABTransactions in Connection with Share Buy-back Program Company Announcement Company Announcement
Genmab A/S has announced the initiation of a share buy-back program aimed at repurchasing up to 2.2 million shares, with transactions executed between May 12 and May 16, 2025. The program, designed to reduce capital and fulfill commitments under the Restricted Stock Unit program, is projected to be completed by July 10, 2025. Following recent transactions, Genmab now holds over 2.4 million shares as treasury shares, representing 3.8% of total share capital. The company emphasizes its commitment to improving patient lives through innovative therapeutics.
Read more →GMAB(a) APPENDIX Share buy-back programme - Specification for May 5-9, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A S 05-May-2025 09 32 27 AM 85 1431.50 XCSE GENMAB A S 05-May-2025 09 36 46 AM 54 1433.50 XCS
Genmab A/S has announced its share buy-back program for the period of May 5-9, 2025. The announcement specifies the exact quantities and prices at which shares will be repurchased, demonstrating Genmab's commitment to returning value to its shareholders. This program may positively influence stock liquidity and investor confidence in the company.
Read more →GMAB▼ -5.7%on this newsshared move
Genmab Announces Financial Results for the First Quarter of 2025
Genmab announced its financial results for the first quarter of 2025, highlighting a significant revenue increase of 19% to $715 million compared to the same period in 2024. The company received approvals for EPKINLY and Tivdak, expanding their treatment indications in Japan and Europe. Financial guidance for 2025 remains unchanged, with projected revenue between $3.3 billion and $3.7 billion. Despite positive sales growth, Genmab experienced a decline in net financial items due to foreign exchange changes and witnessed a rise in operational costs.
Read more →GMABGenmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R 2 ) in Patients with Relapsed Refractory Follicular Lymphoma (FL)
Genmab has announced plans to submit a Supplemental Biologics License Application (sBLA) to the U.S. FDA for its bispecific antibody epcoritamab in combination with rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma. This submission is backed by positive topline results from the Phase 3 EPCORE FL-1 trial, indicating a favorable overall response rate. Safety data align with established profiles of the individual drugs, and no new safety signals have emerged. However, eproitamab plus R2 is not yet approved for use in this indication.
Read more →GMABTransactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark
Genmab A/S announced a share buy-back program to repurchase up to 2.2 million shares, with the goal of reducing capital and fulfilling obligations under its Restricted Stock Unit program. The transactions under this program were executed from April 14 to April 18, 2025, totaling 1,355,531 shares repurchased. The program is expected to be completed by July 10, 2025, and is in accordance with EU regulations. This initiative reflects Genmab's commitment to improve shareholder value while continuing to invest in innovative therapies.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 Company Announcement Net sales of DARZALEX in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net
Genmab A/S announced that DARZALEX (daratumumab) achieved net sales of USD 3,237 million in the first quarter of 2025, with USD 1,829 million from the U.S. and USD 1,409 million from other regions. The company receives royalties on the product's worldwide net sales under an exclusive license with Johnson & Johnson. Genmab aims to revolutionize cancer treatment with innovative antibody medicines and has stated its commitment to improving patient outcomes.
Read more →GMABGenmab A/S Share Capital Reduction Company Announcement COPENHAGEN, Denmark
Genmab A/S announced a share capital reduction of nominally DKK 2,076,853, resulting from the cancellation of 2,076,853 shares. This decision was made during the Annual General Meeting on March 12, 2025, and is expected to enhance shareholder value. The total nominal value of the company's share capital following this reduction will be DKK 64,120,391, represented by an equal number of shares carrying voting rights. Genmab envisions a transformative impact in the treatment of serious diseases by 2030 through its innovative antibody therapeutics.
Read more →GMABTransactions In Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark
Genmab A/S has initiated a share buy-back program aimed at repurchasing up to 2.2 million shares to reduce capital and meet commitments under its Restricted Stock Unit program. As of April 4, 2025, the company executed transactions totaling 402,533 shares for a value of DKK 522,789,533, increasing its treasury shares to 3,165,695, which accounts for 4.78% of total share capital. The program is expected to be completed by July 10, 2025.
Read more →GMABTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark
Genmab A/S announced stock transactions conducted by its managerial employees and their closely associated persons, revealing an acquisition due to vesting of restricted stock units. Elizabeth O'Farrell, a member of the Board of Directors, was involved in the acquisition of 996 shares priced at DKK 0.00. This transaction indicates continued leadership participation in the company's equity, aligning their interests with those of shareholders. The announcement is in compliance with market regulations.
Read more →GMABTransactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark
Genmab A/S announced a share buy-back program on March 25, 2025, aimed at repurchasing up to 2.2 million shares to reduce capital and satisfy commitments under the Restricted Stock Unit program. The program is set to complete by July 10, 2025. Between March 26 and March 28, 2025, the company executed transactions amounting to a total of 233,556 shares for over 319 million DKK. Following these transactions, Genmab holds 2,771,544 shares as treasury shares, representing 4.19% of the total share capital and voting rights.
Read more →GMABGenmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitm
Genmab A/S has announced the launch of a share buy-back program aimed at repurchasing up to 2.2 million shares for a total value of DKK 4.0 billion. The program is set to commence on March 26, 2025, and will last until no later than July 10, 2025, pending any modifications. This initiative is intended to reduce capital and fulfill commitments related to the Restricted Stock Unit program. Genmab has engaged Goldman Sachs International to conduct the buy-backs in line with regulatory compliance.
Read more →GMABGenmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington
Genmab A/S has announced its intention to vigorously defend against a lawsuit filed by AbbVie Inc. in the U.S. District Court for Washington, alleging misappropriation of trade secrets related to its antibody-drug conjugates. AbbVie is seeking damages and injunctive relief. Despite the lawsuit, Genmab's collaboration with AbbVie concerning epcoritamab remains unchanged, and the company aims to expand the development of its clinical-stage product Rina-S for ovarian cancer treatment. Further commentary on the ongoing litigation will be limited until a decision is made.
Read more →GMABPassing of Genmab A/S' Annual General Meeting Company Announcement At Genmab A/S' Annual General Meeting held today
Genmab A/S held its Annual General Meeting in Copenhagen, where the company reported a profit of DKK 7,844 million and discussed its plans for the upcoming year. CEO Dr. Jan van de Winkel presented strategic goals for 2025, while CFO Mr. Anthony Pagano endorsed the annual report for 2024. The meeting concluded with the re-election of several board members and approval of the 2024 Compensation Report.
Read more →GMABConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced the reconstitution of its Board of Directors following the Annual General Meeting. Ms. Deirdre P. Connelly has been appointed as Chair and Ms. Pernille Erenbjerg as Deputy Chair. The company is granting restricted stock units and warrants to incentivize Board members and employees, which could boost alignment with Genmab's long-term goals. The restricted stock units will vest after three years, along with the new warrants, aimed at fostering employee commitment to the company's mission in innovative antibody therapeutics.
Read more →GMAB▼ -9%on this newsshared move
Genmab Announces Johnson & Johnson Decision Regarding HexaBody -CD38 Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and comm
Genmab A/S announced that Johnson & Johnson has chosen not to exercise its option to obtain a worldwide license for HexaBody-CD38, halting further development of the therapy. Despite initial positive clinical data, Genmab will focus on its other assets in late-stage clinical development, including EPKINLY and two wholly owned drugs. The company's confidence in its pipeline remains strong as it allocates resources strategically. Interestingly, there were no new safety issues noted in the daratumumab arm during this evaluation.
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark
Genmab A/S has published a notice regarding the transactions made by its managerial employees and their closely associated persons, including the vesting of restricted stock units. The transactions were conducted outside of a marketplace and incorporated notable figures such as the President & CEO and the CFO. This announcement aligns with regulatory requirements intended to ensure transparency in company operations.
Read more →GMABGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced the grant of 614,676 restricted stock units and 517,191 warrants to its management and employees. The restricted stock units are awarded cost-free and will vest after three years based on performance criteria. Similarly, the warrants, which can be exercised at a set price, will also vest after three years. This program aims to incentivize employees while aligning their interests with the company's long-term growth objectives.
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark
Genmab A/S announced a capital increase of 10,058 shares as a result of employee warrant exercises. This increase, which represents about 0.02% of the company's share capital, is expected to provide approximately DKK 11.4 million to the company. The new shares will be freely transferable and give rights to dividends from the date of subscription. Following registration, the new shares will be listed on Nasdaq Copenhagen.
Read more →GMAB▲ +6.2%on this news
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday
Genmab A/S has announced its Annual General Meeting scheduled for March 12, 2025, at the Copenhagen Marriott Hotel. Shareholders will review the audited Annual Report for 2024 and elect members to the Board of Directors. Key agenda items include reelection of board members, approval of the Compensation Report, and proposed amendments to the Remuneration Policy. Additionally, a capital reduction is proposed through the cancellation of treasury shares.
Read more →GMABGENMAB 2024 ANNUAL REPORT Table of Contents GENMAB 2024 ANNUAL REPORT Management's Review Our 2030 Vision 1 Chair's Statement 3 Letter from the CEO 4 2024 at a Glance 5 Consolidated Key Figures 8 2025 Outlook 10 Our Stra
Genmab A/S has released its 2024 Annual Report, outlining its management reviews, financial performance, and strategic outlook for the upcoming year. The report includes various sections detailing consolidated key figures, a letter from the CEO, and the company's vision for 2030. Additionally, it references ongoing collaborations with partners such as AbbVie, Roche, and Pfizer, reflecting Genmab's focus on antibody product candidates and other initiatives. The document serves as a comprehensive overview of the company's plans and expectations for the future.
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark
Genmab A/S announced the grant of restricted stock units (RSUs) and warrants to its employees, totaling 4,903 RSUs and 5,289 warrants. Each RSU gives the right to receive one share of Genmab stock at a fair value of DKK 1,512, vesting in three years. Similarly, the warrants have an exercise price of DKK 1,512 and will also vest after three years. This initiative reflects Genmab’s ongoing strategy to motivate and retain its workforce while advancing its goals in biotechnology.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for 2024 Company Announcement Net sales of DARZALEX in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, le
Genmab A/S reported worldwide net trade sales of its monoclonal antibody DARZALEX for 2024 reached USD 11,670 million, with sales of USD 6,588 million in the U.S. and USD 5,082 million internationally. The company, known for its focus on developing innovative antibody therapeutics, maintains that it receives royalties from Johnson & Johnson based on these sales. Looking ahead, Genmab aims to transform cancer treatment, although it acknowledges inherent risks associated with clinical trials and market dynamics that could affect its future results.
Read more →GMABGenmab Announces Financial Results for the First Nine Months of 2024
Genmab has announced its financial results for the first nine months of 2024, showcasing a positive adjustment in revenue guidance due to increased royalty revenues from DARZALEX. The company has also reported on successful developments in its late-stage assets, with TEPKINLY receiving additional approval. Furthermore, the operating expenses forecast has been lowered, reflecting Genmab’s focused investment strategy. Overall, these results underscore Genmab's commitment to innovation in antibody-based therapies and improving patient outcomes.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net
Genmab A/S announced that DARZALEX (daratumumab) generated worldwide net sales of USD 3,016 million in the third quarter of 2024. The sales comprised USD 1,684 million from the U.S. and USD 1,332 million from other regions. Genmab earns royalties on these sales through its partnership with Johnson & Johnson, which develops and markets the product. The company aims to lead advancements in cancer therapies with their innovative antibody technologies.
Read more →GMABMajor shareholder announcement for Genmab A/S Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark
Genmab A/S announced that major shareholder Baillie Gifford & Co holds 4.99% of the company’s shares, equating to 3,301,530 voting rights. This company is focused on developing innovative antibody therapeutics intended to improve the lives of patients. With a forward-looking vision, Genmab aims to transform cancer treatments by 2030 through its advanced antibody medicines. The announcement reflects a positive confidence in the company's growth and strategic direction.
Read more →GMABTEPKINLY (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Company Announcement TEPKINLY is the first and only subcutaneous bispecific ant
Genmab A/S announced that the European Commission granted conditional marketing authorization for TEPKINLY (epcoritamab) to treat adults with relapsed or refractory (R/R) follicular lymphoma after two or more lines of therapy. This approval highlights TEPKINLY as the first subcutaneous bispecific T-cell engaging antibody in the EU for this indication. Results from the Phase 1/2 clinical trial demonstrated significant efficacy, with an overall response rate of 83% and concerns regarding safety, particularly related to cytokine release syndrome. The approval provides new options for challenging treatment scenarios in lymphoma management.
Read more →GMABGenmab Announces Financial Results for the First Half of 2024
Genmab A/S has announced its financial results for the first half of 2024, revealing strong growth across its product portfolio. The company reported an increase in revenues primarily driven by its leading products, such as Darzalex and Kesimpta. Financial metrics indicate enhanced profitability, reflecting the effectiveness of its strategic initiatives and collaborations. Overall, the results position Genmab favorably within the competitive biopharma landscape.
Read more →GMABGenmab Updates 2024 Financial Guidance Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acqui
Genmab A/S has revised its financial guidance for 2024, anticipating revenues between DKK 20.5 - 21.7 billion, up from a previous forecast of DKK 18.7 - 20.5 billion. This increase is driven primarily by stronger sales of DARZALEX and Kesimpta. Additionally, while operating profit is projected to rise to DKK 5.3 - 7.1 billion, operating expenses are also expected to increase due to additional R&D investments and integration charges from the ProfoundBio acquisition. The company's overall financial outlook reflects significant growth potential.
Read more →GMAB▼ -7.7%on this newsshared move
Genmab Takes Full Control of Acasunlimab Development Program Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not t
Genmab A/S announced it will assume full responsibility for the development and potential commercialization of acasunlimab after BioNTech opted out of the collaboration. This decision is attributed to BioNTech's portfolio strategy. Despite this, Genmab plans to initiate a Phase 3 study of acasunlimab later this year, which shows promising early results in treating metastatic non-small cell lung cancer. The companies will continue to collaborate on other projects as per their existing agreements.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024 Company Announcement Net sales of DARZALEX in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide ne
Genmab A/S reported strong net sales figures for DARZALEX (daratumumab) in the second quarter of 2024, totaling USD 2,878 million. The substantial sales included USD 1,641 million from the US market and USD 1,237 million from other regions. As the company receives royalties from these sales, it reflects a successful commercial performance for the antibody product. This positive financial outcome supports Genmab's long-term vision of enhancing treatments for patients with cancer and serious diseases.
Read more →GMABEpcoritamab (TEPKINLY ) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE NHL-1
Genmab A/S (Nasdaq: GMAB) announced that the EMA's CHMP has given a positive opinion for the conditional marketing authorization of Epcoritamab (TEPKINLY) for adult patients with relapsed/refractory follicular lymphoma after two or more lines of therapy. This decision recognizes the considerable unmet medical need for patients facing treatment challenges. The recommendation is based on data from the Phase 1/2 EPCORE NHL-1 study, which demonstrated overall and complete response rates. A final decision from the European Commission is expected later in the year.
Read more →GMABCompletion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark
Genmab A/S has successfully completed its share buy-back program, which was initiated on March 15, 2024, with a target to repurchase up to DKK 3.5 billion worth of shares. As of June 26, 2024, a total of 1,821,853 shares were repurchased, representing 4.04% of the company's total share capital. The program is part of Genmab's commitment to creating shareholder value and is compliant with relevant EU regulations. The announcement outlines the details of the transactions and highlights the company's cash flow position.
Read more →GMABEPKINLY (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Company Announcement Approval based on results from Phase 1/2 EPCORE NHL-1 study, which demonstrated
Genmab A/S announced that the U.S. FDA has approved EPKINLY (epcoritamab-bysp) for adults with relapsed or refractory follicular lymphoma after two or more therapeutic lines. This approval is based on favorable results from the Phase 1/2 EPCORE NHL-1 trial, showing a significant response rate. EPKINLY is noted for its unique subcutaneous administration and has received recommendations as a preferred treatment in clinical guidelines. However, its continued approval is subject to the outcomes of ongoing confirmatory trials.
Read more →GMABGenmab Completes Acquisition of ProfoundBio Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical devel
Genmab A/S has successfully completed the acquisition of ProfoundBio, a clinical-stage biotech firm, for USD 1.8 billion. This strategic move provides Genmab with global rights to three antibody-drug conjugates, including Rina-S, which is currently in Phase 1/2 clinical trials for ovarian cancer. Genmab expects this acquisition to enhance its oncology portfolio and create new opportunities for innovative cancer treatments. The transaction is also anticipated to slightly increase Genmab's operating expenses due to additional R&D investments.
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2024
Genmab announced its financial results for the first quarter of 2024, highlighting significant developments such as Priority Review acceptances for EPKINLY and Tivdak by the U.S. FDA. The company is maintaining its revenue guidance for 2024, which expects revenue between DKK 18.7 to 20.5 billion. However, operating expenses are expected to rise due to increased investments in R&D associated with the proposed acquisition of ProfoundBio. Overall, Genmab anticipates a revenue growth driven by strong product performance and ongoing collaborations.
Read more →GMABTIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDA
Genmab A/S and Pfizer Inc. announced that the U.S. FDA has granted full approval for TIVDAK (tisotumab vedotin-tftv) to treat patients with recurrent or metastatic cervical cancer following chemotherapy. This approval follows promising results from the Phase 3 innovaTV 301 trial, which demonstrated improved overall survival compared to traditional chemotherapy. TIVDAK is noted for being the first antibody-drug conjugate to achieve such approval based on substantial survivorship data. While the approval is celebrated for addressing a critical unmet need, the treatment carries a BOXED WARNING for ocular toxicity and has associated adverse reactions.
Read more →GMABTransactions in Connection with Share Buy-Back Program Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced the initiation of a share buy-back program, intending to repurchase up to DKK 3.5 billion worth of shares, expected to conclude by December 16, 2024. From April 22 to April 26, 2024, the company executed various transactions under this program, acquiring a total of 194,117 shares. Currently, Genmab holds 1,463,160 treasury shares, accounting for 2.21% of its total share capital. The initiative follows regulatory guidelines aimed at creating a favorable environment for shareholder value.
Read more →GMABTransactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark
Genmab A/S has initiated a share buy-back program aimed at repurchasing up to DKK 3.5 billion of its shares, which is projected to conclude by December 16, 2024. As of April 19, 2024, a total of 139,367 shares have been repurchased under this program, adding to the treasury shares held by the company. The announcement outlines specific transactions made across various trading platforms, underscoring Genmab's commitment to managing its share capital effectively. This strategic move is part of Genmab's ongoing efforts to improve shareholder value while pursuing its ambitious vision for future antibody therapies.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024 Company Announcement Net sales of DARZALEX in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net
Genmab A/S reported that worldwide net sales of DARZALEX (daratumumab) totaled USD 2,692 million for the first quarter of 2024. This includes USD 1,464 million in the U.S. and USD 1,228 million internationally. Genmab receives royalties on the sales under its exclusive license agreement with Janssen. The company emphasizes its commitment to innovation in antibody therapeutics and aims to transform the lives of patients with serious diseases by 2030.
Read more →GMABGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three ca
Genmab A/S announced the acquisition of ProfoundBio, a clinical-stage biotechnology company, for USD 1.8 billion in cash. This acquisition aims to enhance Genmab's oncology portfolio by adding ProfoundBio's next-generation antibody-drug conjugates (ADCs), including the promising candidate Rina-S for treating ovarian cancer. The deal is expected to close in the first half of 2024, pending customary conditions. Genmab anticipates increased operational expenses due to further R&D but maintains its revenue guidance.
Read more →GMABCompletion of share buy-back program Company Announcement COPENHAGEN, Denmark
Genmab A/S announced the completion of its share buy-back program on March 15, 2024. The program, initiated on February 14, 2024, involved the repurchase of up to 190,000 shares, which was executed according to plan. A total of 13,000 shares were purchased in the final days of the program, bringing the total repurchased shares to 190,000. Following the completion, Genmab now holds 865,972 shares as treasury shares, representing 1.31% of its total share capital.
Read more →GMABGenmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to DKK 3.5 billion worth of shares Completion expected no later than
Genmab A/S announced the initiation of a share buy-back program, set to commence on March 18, 2024, and concluding by December 16, 2024. The company plans to repurchase shares valued at up to DKK 3.5 billion, executing trades through Morgan Stanley Europe SE. Weekly updates will be provided regarding the transactions under this program. Genmab holds 863,972 treasury shares prior to the program initiation, equating to 1.31% of its share capital.
Read more →GMABGenmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on
Genmab A/S has announced a share buy-back program to fulfill commitments related to its Restricted Stock Unit program. The program, set to start on February 15 and run until March 15, 2024, allows for the repurchase of up to 190,000 shares. Danske Bank will manage the buy-back independently. Genmab also holds a number of treasury shares and commits to report weekly on transactions made under this program.
Read more →GMABGENMAB 2023 ANNUAL REPORT Table of Contents Management's Review Our 2030 Vision 2 Chair's Statement 2 Letter from the CEO 3 2023 at a Glance 5 Consolidated Key Figures 6 2024 Outlook 9 Our Strategy 11 Who We Are 13 Busin
Genmab A/S has released its 2023 annual report which outlines the company's financial performance and strategic direction for 2024. The report includes management's overview, the Chair's statement, and significant insights into its vision for 2030. Key financial figures and information regarding various agreements and collaborations are highlighted. However, the document primarily serves as a structured table of contents without specifying detailed outcomes or projections.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for 2023 Company Announcement Net sales of DARZALEX in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Jans
Genmab A/S announced that worldwide net sales of DARZALEX (daratumumab) totaled USD 9,744 million for the year 2023. The sales figures include USD 5,277 million from the U.S. market and USD 4,467 million from international sales. Genmab earns royalties from these sales under its license agreement with Janssen Biotech, Inc. The company aims to transform patient care through innovative antibody-based therapies and continues to invest in strategic partnerships to further its goals.
Read more →GMABGenmab Announces Decision in Arbitration Appeal under License Agreement with Janssen Company Announcement COPENHAGEN, Denmark
Genmab A/S announced that an arbitration appeal concerning its license agreement with Janssen Biotech, Inc. has been denied. This decision concludes the dismissal of Genmab's claims regarding claims for milestone payments and a new royalty term for the subcutaneous formulation of daratumumab. Despite the negative outcome, the decision is stated to have no impact on Genmab's financial guidance for 2024. The company continues to focus on its mission to improve patient lives through antibody therapeutics.
Read more →GMABGrant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced the grant of 10,541 restricted stock units and 7,651 warrants to its board members and employees. The restricted stock units will vest after three years and each warrant allows for the subscription of shares at a set price, also vesting after the same period. This indicates a strategic move to enhance employee engagement and long-term commitment to the company's goals in developing antibody therapeutics.
Read more →GMABMajor Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark
Genmab A/S has announced that Wellington Management Group LLP holds 4.99% of its share capital as of November 8, 2023. This significant stake reflects Wellington's investment in Genmab's innovative approach to developing antibody therapeutics. The company, founded over 20 years ago, continues to focus on creating novel therapies aimed at improving patient outcomes in oncology and serious diseases. The announcement underscores Genmab's ongoing commitment to advancing its drug pipeline and strategic partnerships.
Read more →GMABGenmab Announces Financial Results for the First Nine Months of 2023
Genmab has announced its financial results for the first nine months of 2023, highlighting key developments including regulatory approvals for Epcoritamab in Japan and Europe. The company has updated its revenue guidance for the year upward, citing higher royalties from existing products and increased investment in clinical trials. Despite these positive developments, Genmab faces challenges such as rising operating expenses and risks related to product sales fluctuations. Overall, the outlook for the remainder of 2023 seems proactive, with ongoing advancements in their pipeline.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2023 Company Announcement Net sales of DARZALEX in the third quarter of 2023 totaled USD 2,499 million Genmab receives royalties on worldwide net
Genmab A/S announced that the net sales of its drug DARZALEX (daratumumab) reached USD 2,499 million in the third quarter of 2023. The sales breakdown includes USD 1,369 million from the U.S. and USD 1,130 million from international markets. The company receives royalties on worldwide net sales due to its exclusive license with Janssen. Genmab continues to focus on innovative antibody therapies and has established over 20 strategic partnerships to further its development pipeline.
Read more →GMABGenmab Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement TEPKINLY (epcoritamab) is the first and only
Genmab A/S announced that the European Commission has granted conditional marketing authorization for TEPKINLY (epcoritamab) as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is particularly significant as TEPKINLY is the first and only bispecific antibody for this patient population within the European Union. Clinical trial results demonstrated an overall response rate of 62 percent, highlighting its potential as a valuable treatment option for those facing limited therapeutic alternatives. However, the conditional approval notes that further data will be necessary for continued authorization.
Read more →GMABGenmab and Seagen Announce That TIVDAK (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy Company Announcement
Genmab A/S and Seagen Inc. announced that their Phase 3 innovaTV 301 trial for TIVDAK (tisotumab vedotin-tftv) met its primary endpoint of improving overall survival in patients with recurrent or metastatic cervical cancer compared to chemotherapy. This milestone is crucial as it aims to provide effective treatment options for patients who have limited options. The successful results are intended to support discussions with regulatory authorities for broader application. TIVDAK's safety profile in this trial remained consistent with prior studies, with no new safety concerns identified.
Read more →GMABx200B; ​ Genmab Announces Financial Results for the First Half of 2023 ​
Genmab A/S announced its financial results for the first half of 2023, showcasing a strong performance driven by significant sales growth from its product DARZALEX. The recent FDA approval of EPKINLY as a treatment for relapsed or refractory DLBCL represents a key development for the company. Genmab has adjusted its revenue guidance upward, expecting between DKK 15,500-16,500 million, while anticipating increased operating expenses due to ongoing clinical trials and development efforts. However, there are inherent risks, especially relating to market conditions and financial assumptions.
Read more →GMAB▲ +6.9%on this news
Genmab Updates 2023 Financial Guidance Company Announcement COPENHAGEN, Denmark
Genmab A/S announced its preliminary financial results for the first half of 2023, reporting a 34% increase in revenue and a 10% increase in operating profit compared to the same period last year. The company updated its full-year 2023 financial guidance, projecting revenue between DKK 15,500 and 16,500 million, up from previous estimates. Operating expenses are expected to rise alongside accelerated investments in clinical trials. Although the outlook appears strong, the company noted increased operating expenses and risks associated with clinical development.
Read more →GMABGenmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY ) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement The positive CHMP o
Genmab has announced that the EMA's CHMP has adopted a positive opinion recommending conditional marketing authorization for epcoritamab (TEPKINLY), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This recommendation follows favorable results from the EPCORE NHL-1 trial, which showed an overall response rate of 63.1%. The final decision by the European Commission is expected later this year. If approved, epcoritamab will provide a new therapeutic option for patients facing limited treatment choices.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2023 Company Announcement Net sales of DARZALEX in the second quarter of 2023 totaled USD 2,431 million Genmab receives royalties on worldwide ne
Genmab A/S reported substantial net sales of USD 2,431 million for DARZALEX (daratumumab) in the second quarter of 2023. The sales comprised USD 1,322 million from the U.S. and USD 1,110 million from other global markets. Genmab receives royalties on these worldwide net sales under a license agreement with Janssen. The company emphasizes its commitment to improving patient lives through innovative antibody therapeutics and has multiple strategic partnerships in place to support its mission.
Read more →GMABGenmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE NHL-1 Trial Evaluating Epcoritamab (DuoBody CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Company Announcement Based on
Genmab and AbbVie announced positive topline results from their Phase 1/2 EPCORE NHL-1 trial, highlighting an 82% overall response rate for epcoritamab in patients with relapsed/refractory follicular lymphoma. The trial involved 128 patients and showed no new safety concerns, with the main adverse event being cytokine release syndrome. The companies plan to engage with regulatory authorities to discuss future steps based on these findings. Continued optimization of dosing regimens is underway to reduce the CRS risk.
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcem ent COPENHAGEN, Denmark
Genmab A/S has announced a capital increase due to the exercise of employee warrants, resulting in the issuance of 19,395 new shares. These shares are subscribed for in cash at various prices, collectively raising approximately DKK 26.9 million for the company. The shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. This increase represents about 0.03% of Genmab's total share capital, reflecting the company's ongoing efforts to strengthen its financial position.
Read more →GMABTransactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced transactions involving its shares by managerial employees and their closely associated persons, in accordance with market regulations. The transactions include multiple sales of shares at varying prices, indicating a significant level of trading activity. This disclosure aligns with Genmab's commitment to transparency and regulatory compliance, enhancing shareholder trust.
Read more →GMABEPKINLY (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Company Announcem
Genmab A/S announced that the U.S. FDA has approved EPKINLY (epcoritamab-bysp), the first bispecific antibody for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval, based on significant clinical response rates, aims to address a critical need for treatment options in this patient population after failure of prior therapies. The award highlights Genmab's ongoing commitment to developing innovative therapies in oncology, although its continued approval will depend on the outcomes of further confirmatory trials. EPKINLY introduces the opportunity for improved management of a challenging disease.
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2023
Genmab has announced its financial results for the first quarter of 2023, reporting a revenue of DKK 2,854 million and net profit of DKK 226 million. The company is focusing on the approval of epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and has outlined its financial guidance for the year, projecting revenues of DKK 14,600 - 16,100 million. However, there are rising operating expenses and risks associated with COVID-19 and regulatory approvals that could impact projected outcomes. A conference call will be held today to further discuss these results.
Read more →GMABGenmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen Company Announcement COPENHAGEN, Denmark
Genmab A/S has announced its intention to file an appeal concerning the dismissal of its claims in the second arbitration with Janssen Biotech regarding the daratumumab license. This appeal will be handled by a single arbitrator under specific dispute resolution rules. While the arbitration process remains confidential, Genmab's ongoing commitment to innovating antibody therapeutics is underscored by its extensive pipeline and strategic partnerships. The outcome of this arbitration could have significant implications for Genmab's future collaborations and development efforts.
Read more →GMABGenmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen Company Announcement COPENHAGEN, Denmark
Genmab A/S announced the initial resolution of its second arbitration under the license agreement with Janssen Biotech regarding daratumumab. The arbitral tribunal dismissed Genmab's claims, ruling that they should have been raised in the first arbitration. Genmab retains the right to review this decision within a limited timeframe and continues to have ongoing collaborations with Janssen. Importantly, the arbitration outcome does not affect Genmab's financial guidance as provided in earlier communications.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2023 Company Announcement Net sales of DARZALEX in the first quarter of 2023 totaled USD 2,264 million Genmab receives royalties on worldwide net
Genmab A/S announced that its product DARZALEX (daratumumab) generated net sales of USD 2,264 million in the first quarter of 2023, according to a report by Johnson & Johnson. The sales breakdown shows USD 1,191 million from the U.S. and USD 1,072 million from the rest of the world. Genmab receives royalties from the worldwide sales, benefiting from their exclusive license with Janssen for daratumumab. The company emphasizes its commitment to advancing antibody therapeutics through innovative technologies and strategic partnerships.
Read more →GMABConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark
Following the Annual General Meeting on March 29, 2023, Genmab A/S has appointed new members to its Board of Directors and awarded restricted stock units and warrants to management and employees. Deirdre P. Connelly has been appointed Chair, while Pernille Erenbjerg serves as Deputy Chair. The company granted 90,054 restricted stock units with performance criteria and 16,276 warrants to enhance employee incentives. The structures of these awards are designed to align with Genmab's goal of advancing innovative therapeutics.
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise COPENHAGEN, Denmark
Genmab A/S will increase its share capital by 24,359 shares due to the exercise of employee warrants, without preemption rights for existing shareholders. The shares were subscribed in cash at varying prices, collectively raising about DKK 31.8 million. Following the increase, the total nominal value of the company's share capital will rise to DKK 65,985,932. The new shares will be listed on Nasdaq Copenhagen and will grant holders all typical shareholder rights, including dividends.
Read more →GMABGenmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 220,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on
Genmab A/S has announced the initiation of a share buy-back program to fulfill commitments made under its Restricted Stock Unit program. This program, set to run from February 23, 2023, through March 31, 2023, will allow the company to repurchase up to 220,000 shares. Danske Bank will manage the buy-back independently. The announcement highlights Genmab's ongoing strategy to enhance shareholder value and commitment to their financial obligations.
Read more →GMABGENMAB 2022 ANNUAL REPORT Table of Contents Management's Review Our Vision 2 Chair's Statement 2 Letter from the CEO 3 2022 at a Glance 4 Consolidated Key Figures 6 2023 Outlook 9 Our Strategy 11 Who We Are 13 Business M
The 2022 annual report for Genmab A/S outlines key financial figures, strategic outlook, and management commentary. It covers important milestones and development partnerships that shape the company's future. The report emphasizes a vision for continued growth and reflects on the achievements of the past year. However, specific risks or challenges were not highlighted.
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for 2022 Company Announcement Net sales of DARZALEX in 2022 totaled USD 7,977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Jans
Genmab A/S announced that worldwide net sales of DARZALEX, including its subcutaneous form, reached USD 7,977 million in 2022. The majority of these sales came from the U.S., with USD 4,210 million reported domestically and USD 3,767 million from other markets. This revenue is significant for Genmab, as it receives royalties under its license agreement with Janssen Biotech. The announcement underscores Genmab's commitment to developing innovative therapies alongside a robust pipeline of products.
Read more →GMABCorrection to Company Announcement No. 1 of
Genmab A/S issued a correction to its Company Announcement No. 1 from January 3, 2023, regarding transactions related to shares and linked securities. The correction specifies that Mijke Zachariasse, a board member, acquired 297 shares instead of the previously reported 175 shares due to the vesting of restricted stock units. This adjustment is significant for transparency according to regulatory obligations. The company continues to engage in various strategic partnerships and aims to innovate in antibody therapeutics.
Read more →GMABGrant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement Company Announcement COPENHAGEN, Denmark
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement Company Announcement COPENHAGEN, Denmark; November 21, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 11,608 restr
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relati
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; November 14, 2022 - Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on M
Read more →GMABGenmab Announces Financial Results for the First Nine Months of 2022
Genmab Announces Financial Results for the First Nine Months of 2022 November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2022 "During the first nine months of the year we continued to build on Genmab's consistent track record of s
Read more →GMABGenmab Improves Its 2022 Financial Guidance Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark
Genmab Improves Its 2022 Financial Guidance Company Announcement COPENHAGEN, Denmark; November 3, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on August 8, 2022. The improved guidance is driven primarily by the posi
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for the Third Quarter of 2022 Company Announcement Net sales of DARZALEX in the third quarter of 2022 totaled USD 2,052 million Genmab receives royalties on worldwide
Genmab Announces Net Sales of DARZALEX (daratumumab) for the Third Quarter of 2022 Company Announcement COPENHAGEN, Denmark; October 18, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneou
Read more →GMABx200B; ​ Genmab Announces Financial Results for the First Half of 2022 ​
Genmab Announces Financial Results for the First Half of 2022 August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Genmab's innovation was on display during the second quarter of 2022 with data presentations at multiple prestigious c
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for the Second Quarter of 2022 Company Announcement Net sales of DARZALEX in the second quarter of 2022 totaled USD 1,986 million Genmab receives royalties on worldwid
Genmab Announces Net Sales of DARZALEX (daratumumab) for the Second Quarter of 2022 Company Announcement COPENHAGEN, Denmark; July 19, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous
Read more →GMABGenmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody -CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody -CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Company Announcement COPENHAGEN, Denmark; July 18, 2022 -
Read more →GMABGenmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody -CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Company Announcement COPENHAGE
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody -CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Company Announcement COPENHAGEN, Denmark; June 30, 2022 - Genmab A/S (Nasdaq: GMAB) toda
Read more →GMAB▲ +6.4%on this newsshared move
Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 370,000 shares Mitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit program Co
Genmab Announces Initiation of Share Buy-Back Program Company Announcement COPENHAGEN, Denmark; June 17, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program to mitigate dilution from warrant exercises and honor our commitments under o
Read more →GMABGenmab Commences New Arbitration Under License Agreement With Janssen Company Announcement COPENHAGEN, Denmark
Genmab Commences New Arbitration Under License Agreement With Janssen Company Announcement COPENHAGEN, Denmark; June 9, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denm ark
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 17, 2022 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase is effect
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2022
Genmab Announces Financial Results for the First Quarter of 2022 May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 "During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2022 Company Announcement Net sales of DARZALEX in the first quarter of 2022 totaled USD 1,856 million Genmab receives royalties on worldwide net
Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2022 Company Announcement COPENHAGEN, Denmark; April 19, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC)
Read more →GMABGenmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody -CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) Company Announcement Based on the topline results from
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody -CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Illinois; APRIL 13, 2022 - Genmab A/S (Nasdaq: GMAB)
Read more →GMABGenmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement Company Announcement COPENHAGEN, Denmark
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement Company Announcement COPENHAGEN, Denmark; April 8, 2022 - Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising
Read more →GMABConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announceme
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; March 29, 2022 - Genmab A/S (Nasda
Read more →GMABGenmab Announces the Nomination of a New Member of the Company's Board of Directors Company Announcement Genmab's Board of Directors proposes that Elizabeth O'Farrell is elected as a new member of the Board of Directors
Genmab Announces the Nomination of a New Member of the Company's Board of Directors Company Announcement COPENHAGEN, Denmark; March 14, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that the Company's Board of Directors nominates Elizabeth O'Farrell for election as a new mem
Read more →GMABNotice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Tuesday
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement COPENHAGEN, Denmark; February 24, 2022 - Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, Kalvebod Brygge 5,
Read more →GMAB12-31 2021 FY false P5Y 0.0225 0 P5Y P1Y P5Y 3 Genmab A/S 6-K 2021-12-31 0001434265 gmab:RestrictedStockUnitsRSUsMember 2021-12-31 0001434265 gmab:RestrictedStockUnitsRSUsMember 2020-12-31 0001434265 gmab:RestrictedStock
0.100.100001434265--12-312021FYfalseP5Y0.02250P5YP1YP5Y3Genmab A/S6-K2021-12-310001434265gmab:RestrictedStockUnitsRSUsMember2021-12-310001434265gmab:RestrictedStockUnitsRSUsMember2020-12-310001434265gmab:RestrictedStockUnitsRSUsMember2019-12-310001434265gmab:EquipmentFurnitureAnd
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for 2021 Company Announcement Net sales of DARZALEX in 2021 totaled USD 6,023 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copen
Genmab Announces Net Sales of DARZALEX (daratumumab) for 2021 Company Announcement Copenhagen, Denmark; January 25, 2022 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (d
Read more →GMAB▼ -6.4%on this news
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement Copenhagen, Denmark
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement Copenhagen, Denmark; November 22, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 7,959 restricte
Read more →GMAB▼ -6%on this news
Genmab Announces Financial Results for the First Nine Months of 2021
Genmab Announces Financial Results for the First Nine Months of 2021 November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021 "The U.S. FDA approval for TIVDAK represents an important milestone both for the treatment of cervical
Read more →GMABGenmab Improves its 2021 Financial Guidance Company Announcement Genmab improves its 2021 financial guidance COPENHAGEN, Denmark
Genmab Improves its 2021 Financial Guidance Company Announcement COPENHAGEN, Denmark; November 4, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance published on August 11, 2021. The improved guidance is driven primarily by increas
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for the Third Quarter of 2021 Company Announcement Net sales of DARZALEX in the third quarter of 2021 totaled USD 1,580 million Genmab receives royalties on worldwide
Genmab Announces Net Sales of DARZALEX (daratumumab) for the Third Quarter of 2021 Company Announcement Copenhagen, Denmark; October 19, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneou
Read more →GMABGenmab and Seagen Announce FDA Accelerated Approval for TIVDAK TM (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Company Announcement TIVDAK is a First-in-Class Antibody-Drug Conju
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAKTM (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Company Announcement COPENHAGEN, Denmark, and BOTHELL, Wash.; DATE, 2021 - Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq:
Read more →GMABThe Board of Directors shall receive an annual remuneration the size of which shall be stated in the Annual Report.
(English translation of Articles of Association) Articles of Association Formerly A/S registration no.: 248.498) Name, Registered Office, Objects and Group Language The name of the Company is Genmab A/S. The registered office of the Company shall be in the municipality of Co
Read more →GMABGenmab Announces Financial Results for the First Half of 2021
Genmab Announces Financial Results for the First Half of 2021 August 11, 2021; Copenhagen, Denmark; Interim Report for the First Half of 2021 Genmab's antibody expertise and innovation were on display during the second quarter of 2021 with the U.S. FDA's acceptance for priorit
Read more →GMABMajor Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark
Major Shareholder Announcement Company Announcement Copenhagen, Denmark; July 21, 2021 - Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners Limited Partnership has informed us that, as of July 16, 2021, Arti
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for the Second Quarter of 2021 Company Announcement Net sales of DARZALEX in the second quarter of 2021 totaled USD 1,433 million Genmab receives royalties on worldwid
Genmab Announces Net Sales of DARZALEX (daratumumab) for the Second Quarter of 2021 Company Announcement Copenhagen, Denmark; July 21, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous
Read more →GMABGenmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis Company Announcement Copenhagen, Denmark; June 22, 2021 -
Read more →GMABGenmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis Company Announcement Janss
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis Company Announcement Copenhagen, Denmark; May 21, 2021 - Genmab A/S (Nasdaq: GMAB) a
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2021
Genmab Announces Financial Results for the First Quarter of 2021 May 5, 2021; Copenhagen, Denmark; Genmab Interim Report for the First Quarter Ended March 31, 2021 "In 2020, Genmab reached an inflection point in our evolution into a fully integrated biotech innovation powerhou
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2021 Company Announcement Net sales of DARZALEX in the first quarter of 2021 totaled USD 1,365 million Genmab receives royalties on worldwide net
Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2021 Company Announcement Copenhagen, Denmark; April 20, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous form
Read more →GMABConstitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab Company Announcement COPENHAGEN, Denmark
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab Company Announcement COPENHAGEN, Denmark; April 13, 2021 - Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General
Read more →GMABGenmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Company Announcement FDA action date
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Company Announcement COPENHAGEN, Denmark and BOTHELL, Wash.; April 09, 2021 - Genmab A/S (Nasda
Read more →GMAB(a) APPENDIX Share buy-back programme - Specification for March 29 to 31 , 2021 43 2029 XCSE 20210329 15:52:58.060000 34 2029 XCSE 20210329 15:52:58.060000 9 2029 XCSE 20210329 15:52:58.060000 26 2026 XCSE 20210329 15:56
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for March 29 to 31 , 2021 Volume Price Venue Time CET 1 2024 XCSE 20210331 9:00:04.085000 22 2024 XCSE 20210331 9:00:04.085000 22 2024 XCSE 20210331 9:00:05.519000 5 2024 XCSE 20210331 9:00:05.519000 22 201
Read more →GMABGenmab Announces European Marketing Authorization for Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis Company Announcement Novartis receives European approval for Kesimpta (ofatumumab) for the treatment of relapsin
Genmab Announces European Marketing Authorization for Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis Company Announcement Copenhagen, Denmark; March 30, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted Novartis marketing auth
Read more →GMABNotice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold wholly virtual Annual General Meeting on
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement COPENHAGEN, Denmark; March 9, 2021 - Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Tuesday, April 13, 2021 at 14:00 PM CET. Due to the COVID-19 pandemic the annual general meeting
Read more →GMABGenmab announces initiation of share buy-back program Company Announcement Repurchase of up to 200,000 shares Mitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit program Co
Genmab announces initiation of share buy-back program Company Announcement COPENHAGEN, Denmark; February 23, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program to mitigate dilution from warrant exercises and honor our commitments und
Read more →GMAB(a) Delivering on Our Commitment 2020 Annual Report Genmab A/S CVR No. 21 02 38 84 Table of Contents Management's Review Financial Statements Using Science to Turn Insights into Medicine Our Purpose To improve the lives
Arzerra is a trademark of Novartis Pharma AG. Kesimpta and Sensoready are trademarks of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Johnson & Johnson. OmniAb is a trademark of Photograph credits: Tuala Hjarn , 3FX, Inc., Andrei Jackamets and Conn
Read more →GMABGenmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines Company Announcement COPENHAGEN, Denmark
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines Company Announcement COPENHAGEN, Denmark; February 22, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been
Read more →GMABGenmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Company Announcement Submission based on positive pivotal innovaTV 204 tr
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Company Announcement COPENHAGEN, Denmark and BOTHELL, Wash.; Feb 10, 2021 - Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN
Read more →GMABCHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis Company Announcement Novartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of mul
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis Company Announcement Copenhagen, Denmark; January 29, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines A
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons f) Place of the transaction Outside a market place 1. Details of the person discharging manag
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement Copenhagen, Denmark; January 27, 2021 - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing
Read more →GMABGenmab Announces 2020 Net Sales of DARZALEX (daratumumab) Company Announcement Net sales of DARZALEX in 2020 totaled USD 4,190 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhage
Genmab Announces 2020 Net Sales of DARZALEX (daratumumab) Company Announcement Copenhagen, Denmark; January 26, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous formulation (sold under
Read more →GMABGenmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis Company Announcement DARZALEX FASPR
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis Company Announcement Copenhagen, Denmark; January 15, 2021 - Genmab A/S (Nasdaq: GMAB) announ
Read more →GMABGenmab Achieves USD 40 Million Milestone in Collaboration with AbbVie Company Announcement Genmab to receive USD 40 million milestone payment from AbbVie Milestone triggered by progress in Phase 3 study of epcoritamab in
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie Company Announcement Copenhagen, Denmark; January 13, 2021 - Genmab A/S (Nasdaq: GMAB) announced today that it has reached the first milestone in its collaboration with AbbVie. A USD 40 million milestone paym
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement Copenhagen, Denmark
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement Copenhagen, Denmark; January 5, 2021 - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing R
Read more →GMABGenmab Announces Enapotamab Vedotin Update Company Announcement Genmab will not advance the development of enapotamab vedotin Data from expansion cohorts did not meet stringent criteria for proof-of-concept Genmab to pri
Genmab Announces Enapotamab Vedotin Update Company Announcement Copenhagen, Denmark; November 24, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin. While enapotamab vedotin has shown some evidence of clinical activi
Read more →GMABCapital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement Copenhagen, Denmark
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement Copenhagen, Denmark; November 10, 2020 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,402 shares as a consequence of the exercise of employee warrants. The increase is e
Read more →GMABGenmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development pl
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Company Announcement Copenhagen, Denmark; November 5, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that it will initiate a Phase 3 study of epcoritama
Read more →GMABGenmab Announces Financial Results for the First Nine Months of 2020
Genmab Announces Financial Results for the First Nine Months of 2020 November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 "Genmab continued to deliver on the promise of improving the lives of patients, with multiple regulator
Read more →GMABGenmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis Company Announcement Second part of t
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis Company Announcement Copenhagen, Denmark; October 21, 2020 - Genmab A/S (Nasdaq: GMAB) announce
Read more →GMABGenmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2020 Company Announcement Net sales of DARZALEX in the third quarter of 2020 totaled USD 1,099 million Genmab receives royalties on worldwide net
Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2020 Company Announcement Copenhagen, Denmark; October 13, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous fo
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement Copenhagen, Denmark
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement Copenhagen, Denmark; October 7, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 14,187 restricted stock units and 43,941 warrants to empl
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons About Genmab Genmab is a publicly traded, international biotechnology company specializing in
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement Copenhagen, Denmark; September 30, 2020 - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementin
Read more →GMABGenmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen Company Announcement Copenhagen, Denmark
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen Company Announcement Copenhagen, Denmark; September 22, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license a
Read more →GMABGenmab Announces Janssen Granted U.S. FDA Approval for DARZALEX (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Company Announcement DARZALEX (daratumumab) appro
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Company Announcement Copenhagen, Denmark; August 20, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that
Read more →GMABGenmab Announces Plan to Transition Arzerra (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S. Company Announcement Novartis intends to transition availability of Arzerra (of
Genmab Announces Plan to Transition Arzerra (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S. Company Announcement Copenhagen, Denmark; August 20, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that Novartis intends to transition
Read more →GMABU.S. FDA Approves Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis Company Announcement Kesimpta (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adults First B-cell th
U.S. FDA Approves Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis Company Announcement Copenhagen, Denmark; August 20, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of Kesimpta (ofatumumab) inje
Read more →GMABGenmab Announces Financial Results for the First Half of 2020
Genmab Announces Financial Results for the First Half of 2020 August 12, 2020; Copenhagen, Denmark; Interim Report for the First Half of 2020 "At Genmab our core purpose is to improve the lives of patients by creating differentiated antibody medicines. Despite the unprecedente
Read more →GMABGenmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myelom
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Company Announcement Copenhagen, Denmark; July 31, 2020
Read more →GMABGenmab Announces Net Sales of DARZALEX for the Second Quarter of 2020 Company Announcement Net sales of DARZALEX in the second quarter of 2020 totaled USD 901 million Genmab will receive royalties on worldwide net sales
Genmab Announces Net Sales of DARZALEX for the Second Quarter of 2020 Company Announcement Copenhagen, Denmark; July 16, 2020 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net sales of DARZALEX (daratumumab), including sales of the subcutaneous formulation, as repo
Read more →GMABGenmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer Company Announcement Genmab and Seattle Genetics plan to discuss the results wit
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer Company Announcement Copenhagen, Denmark; June 29, 2020 - Genmab A/S (Nasdaq: GMAB) today announced very favorable topline results from th
Read more →GMABGenmab and AbbVie Announce Broad Oncology Collaboration Company Announcement · Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific a
Genmab and AbbVie Announce Broad Oncology Collaboration Company Announcement Copenhagen, Denmark and North Chicago, Illinois; June 10, 2020 Genmab A/S (Nasdaq: GMAB) and AbbVie Inc. (NYSE: ABBV) announced today that Genmab and AbbVie have signed a broad collaboration agreement
Read more →GMABGenmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX ® (daratumumab) for the Treatment of Patients with Multiple Myeloma Company Announcement · Subcutaneous fixed-dosed
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with Multiple Myeloma Company Announcement Copenhagen, Denmark; June 4, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Co
Read more →GMABGenmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis Company Announcement · Phase III ANDROMEDA study of subcutaneous daratumumab in combination with
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis Company Announcement Copenhagen, Denmark; May 28, 2020 Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the Phase III ANDROMEDA (AMY3001)
Read more →GMABGenmab Announces Financial Results for the First Quarter of 2020
Genmab Announces Financial Results for the First Quarter of 2020 May 6, 2020; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2020 Despite the unprecedented challenges posed by the coronavirus (COVID-19) pandemic, we will continue to invest in our inn
Read more →GMABGenmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO ™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma Company Announcement ·
Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma Company Announcement Copenhagen, Denmark; May 01, 2020 Genmab A/S (Nasdaq: GMAB) announced to
Read more →GMABCHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma Company Announcement · Committee for Medicinal Products for Human Use issued Posi
CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma Company Announcement Copenhagen, Denmark; April 30, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for
Read more →GMABGenmab Announces Net Sales of DARZALEX ® (daratumumab) for First Quarter of 2020 Company Announcement · Net sales of DARZALEX ® in the first quarter of 2020 totaled USD 937 million · Genmab will recei
Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2020 Company Announcement Copenhagen, Denmark; April 14, 2020 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 9
Read more →GMABConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and a New Member of Management, and Grant of Restricted Stock Units and Warrants to Employ
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and a New Member of Management, and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab Company Announ
Read more →GMABPassing of Genmab A/S' Annual General Meeting Company Announcement · At Genmab A/S' Annual General Meeting held today
Passing of Genmab A/S' Annual General Meeting Company Announcement Copenhagen, Denmark; March 26, 2020 Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Chairman of the Board of Directors Mr.
Read more →GMABGenmab A/S Provides Update to Annual General Meeting Media Release Copenhagen, Denmark
Genmab A/S Provides Update to Annual General Meeting Copenhagen, Denmark, March 12, 2020 Genmab A/S (Nasdaq: GMAB) announces additional information regarding its Annual General Meeting 2020. At present, the company intends to conduct the Annual General Meeting as planned. To co
Read more →GMABGenmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer Company Announcement Copenhagen, Denmark
Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer Company Announcement Copenhagen, Denmark; March 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that Anthony Mancini will join the company as Executive Vice President and Chi
Read more →GMABNotice to Convene the Annual General Meeting of Genmab A/S Company Announcement · Genmab A/S to hold Annual General Meeting on
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Copenhagen, Denmark; February 27, 2020 Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 26, 2020 at 14:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, D
Read more →GMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1. Details of the person discharging managerial responsibilities/person closely associated a)
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement Copenhagen, Denmark; February 26, 2020 In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing R
Read more →GMABGenmab Board of Directors Chairman to Step Down Company Announcement Copenhagen, Denmark
Genmab Board of Directors Chairman to Step Down Company Announcement Copenhagen, Denmark; February 21, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the Chairman of the Board of Directors, Mr. Mats Pettersson, B.Sc., has decided to step down from the Board at Genmab A/S'
Read more →GMABInnovating antibodies, improving lives Annual Report 2019 Genmab A/S CVR No. 21 02 38 84 Table of Contents Management's Review Financial Statements Genmab In Short ................................... 4 — HuMax-IL8
Design & Layout Kontrapunkt Photographers Tuala Hjarn , 3FX, Inc. Forward Looking Statement 159 Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark T. +45 70 20 27 28 Genmab US, Inc. 902 Carnegie Center Suite 301 Princeton, NJ 08540 USA T. +1 609 430 2481 Genmab B.V. & Genmab
Read more →GMABGenmab Announces 2019 Net Sales Figures for DARZALEX ® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen Company Announcement · Net trade sales of DARZALEX
Genmab Announces 2019 Net Sales Figures for DARZALEX (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen Company Announcement Copenhagen, Denmark; January 22, 2020 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net t
Read more →GMABGenmab Announces European Marketing Authorization for DARZALEX ® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement · DARZALEX ®
Genmab Announces European Marketing Authorization for DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement Copenhagen, Denmark; January 20, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the
Read more →GMABGenmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics Company Announcement · Genmab and CureVac enter broad strategic partnership · Companies to conduct joint research on fi
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics Company Announcement Copenhagen, Denmark and T bingen, Germany, December 19, 2019 Genmab A/S (Nasdaq: GMAB) and CureVac AG announced today that Genmab and CureVac have entered into a rese
Read more →GMABCHMP Issues Positive Opinion Recommending DARZALEX ® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement · CHMP issued positive opinion
CHMP Issues Positive Opinion Recommending DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement Copenhagen, Denmark; December 13, 2019 Genmab A/S (Nasdaq: GMAB) announced today that the Committee
Read more →GMABGrant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement Copenhagen, Denmark
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Company Announcement Copenhagen, Denmark; December 5, 2019 Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 83,658 restr
Read more →GMABGenmab Achieves USD 100 Million Sales Milestone in DARZALEX ® (daratumumab) Collaboration with Janssen Company Announcement · Genmab to receive milestone payment of USD 100 Million in DARZALEX collaboration &#x
Genmab Achieves USD 100 Million Sales Milestone in DARZALEX (daratumumab) Collaboration with Janssen Company Announcement Copenhagen, Denmark; December 5, 2019 Genmab A/S (Nasdaq: GMAB) announced today that it has achieved a USD 100 million sales volume milestone in its DARZALE
Read more →GMABGenmab Announces European Marketing Authorization for DARZALEX ® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement · DARZALEX ® approved in
Genmab Announces European Marketing Authorization for DARZALEX (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement Copenhagen, Denmark; November 19, 2019 Genmab A/S (Nasdaq: GMAB) announced today that the European
Read more →GMABInterim Report for the Nine Months Ended
Interim Report for the Nine Months Ended September 30, 2019 November 6, 2019; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2019 Genmab made excellent progress across many areas of the business during the third quarter of 2019. Of key signif
Read more →GMABDavid Eatwell to Retire as Chief Financial Officer of Genmab Company Announcement · David Eatwell has decided to retire on
David Eatwell to Retire as Chief Financial Officer of Genmab Company Announcement Copenhagen, Denmark; October 30, 2019 Genmab A/S (Nasdaq: GMAB) announced today that David Eatwell, Executive Vice President and Chief Financial Officer, has decided to retire on February 29, 2020
Read more →GMABCHMP Issues Positive Opinion Recommending DARZALEX ® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement · CHMP issued a positive opinion for DARZ
CHMP Issues Positive Opinion Recommending DARZALEX (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement Copenhagen, Denmark; October 18, 2019 Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicina
Read more →GMABGenmab Announces Net Sales of DARZALEX ® (daratumumab) for Third Quarter of 2019 Company Announcement · Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 million · Genmab will receive roya
Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2019 Company Announcement Copenhagen, Denmark; October 15, 2019 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 765 m
Read more →GMABGrant of Restricted Stock Units and Warrants to Employees in Genmab Copenhagen, Denmark
Grant of Restricted Stock Units and Warrants to Employees in Genmab Copenhagen, Denmark; October 11, 2019 Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 17,653 restricted stock units and 62,848 warrants to employees of the company an
Read more →GMABGenmab Announces U.S. FDA Approval of DARZALEX ® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma Company Announcement · DARZALEX (daratumumab) approved
Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma Company Announcement Copenhagen, Denmark; September 26, 2019 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food an
Read more →GMABGenmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Company Announcement · Phase III CANDOR study
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Company Announcement Copenhagen, Denmark; September 13, 2019 Genmab A/S (Nasdaq: GMAB) announced today toplin
Read more →GMABDetailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS Company Announcement · Details from the ASCLEPIOS I & II studies of subcu
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS Company Announcement Copenhagen, Denmark; September 13, 2019 Genmab A/S (Nasdaq: GMAB) announced that its partner for ofatumumab, Novart
Read more →GMABGenmab's Partner for Ofatumumab, Novartis, Reports that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies Company Announcement · In ASCLEPIOS I and II,
Genmab's Partner for Ofatumumab, Novartis, Reports that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies Company Announcement Copenhagen, Denmark; August 30, 2019 Genmab A/S (Nasdaq: GMAB) announced today that its
Read more →GMABGenmab Announces Approval of DARZALEX ® (daratumumab) in Frontline Multiple Myeloma in Japan Company Announcement · DARZALEX ® approved in combination with bortezomib, melphalan and prednisone for the trea
Genmab Announces Approval of DARZALEX (daratumumab) in Frontline Multiple Myeloma in Japan Company Announcement Copenhagen, Denmark; August 22, 2019 Genmab A/S (Nasdaq: GMAB) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the use of
Read more →GMABGenmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance August 14, 2019; Copenhagen, Denmark; Interim Report for the First Half of 2019 The first half of 2019 brought truly transformational change to Genmab as we began the process of b
Read more →GMABGenmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase Company Announcement · Genmab A/S has t
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase Company Announcement Copenhagen, Denmark; July 23, 2019 Genmab A/S (Nasdaq: GMAB) announced today the
Read more →GMABGenmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase Company Announcement · Genmab A/S has today completed its
Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase Company Announcement Copenhagen, Denmark; July 22, 2019 Genmab A/S (CSE: GEN, Nasdaq: GMAB) announced today the closing
Read more →Competitive Position
How GMAB ranks across every disease it competes inCompetitive Position is a premium feature
See how GMAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial